Precision medicine has grown in the last decade, from a fairly niche academic endeavor to a major force in oncology.
However, with the great promise of precision medicine comes increasing complexity and tactical considerations required to bring new targeted therapies to the point of care.
In order to overcome these challenges and better enable end users to advance the practice of precision medicine, high sensitivity assays need to be designed to detect all relevant variants. Having the complementary interpretation solution designed to handle the complexity and diversity of the data proves to be critical.
This white paper describes QCI Precision Insights, a professional clinical interpretation service from N-of-One, now a Qiagen company. Powered by a world-class team of molecular biologists and oncologists, QCI Precision Insights delivers concise clinical evidence for each biomarker in the context of the cancer subtype, listing information on the mutation’s molecular characteristics, roles in disease, and therapeutic, prognostic, and diagnostic implications.
Offered Free by: Qiagen
See All Resources from: Qiagen